PE20030277A1 - Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa - Google Patents

Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa

Info

Publication number
PE20030277A1
PE20030277A1 PE2002000652A PE2002000652A PE20030277A1 PE 20030277 A1 PE20030277 A1 PE 20030277A1 PE 2002000652 A PE2002000652 A PE 2002000652A PE 2002000652 A PE2002000652 A PE 2002000652A PE 20030277 A1 PE20030277 A1 PE 20030277A1
Authority
PE
Peru
Prior art keywords
chromane
pharmaceutical composition
composition including
dopa
fluorophenil
Prior art date
Application number
PE2002000652A
Other languages
English (en)
Spanish (es)
Inventor
Christoph Seyfried
Herrmann Russ
Frank Weber
Gerd Bartoszyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20030277A1 publication Critical patent/PE20030277A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2002000652A 2001-07-26 2002-07-24 Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa PE20030277A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26

Publications (1)

Publication Number Publication Date
PE20030277A1 true PE20030277A1 (es) 2003-03-25

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000652A PE20030277A1 (es) 2001-07-26 2002-07-24 Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa

Country Status (23)

Country Link
US (1) US7872030B2 (https=)
EP (1) EP1408964B1 (https=)
JP (1) JP2004538289A (https=)
KR (1) KR20040029325A (https=)
CN (1) CN1292749C (https=)
AR (1) AR037496A1 (https=)
AT (1) ATE352302T1 (https=)
AU (1) AU2002355170B2 (https=)
BR (1) BR0211358A (https=)
CA (1) CA2455621C (https=)
CY (1) CY1107616T1 (https=)
DE (1) DE60217870T2 (https=)
DK (1) DK1408964T3 (https=)
ES (1) ES2280602T3 (https=)
HU (1) HUP0402092A3 (https=)
MX (1) MXPA04000775A (https=)
MY (1) MY134059A (https=)
PE (1) PE20030277A1 (https=)
PL (1) PL208258B1 (https=)
PT (1) PT1408964E (https=)
RU (1) RU2297833C2 (https=)
SI (1) SI1408964T1 (https=)
WO (1) WO2003009835A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
PT2161038E (pt) 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Composições e suas utilizações dirigidas à huntingtina
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
EP3626823A1 (en) * 2009-09-11 2020-03-25 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
EP0465254B1 (en) 1990-07-06 1996-11-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused thiophene compounds and uses thereof
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
AU3929493A (en) 1992-03-11 1993-10-05 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
PT707007E (pt) * 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
US6242456B1 (en) 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
CN1155567C (zh) 1998-04-29 2004-06-30 惠氏公司 抑制精神的吲哚基衍生物
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
PL367291A1 (en) 2005-02-21
HUP0402092A2 (hu) 2005-02-28
RU2297833C2 (ru) 2007-04-27
AR037496A1 (es) 2004-11-17
AU2002355170B2 (en) 2007-06-07
DE60217870D1 (de) 2007-03-15
DE60217870T2 (de) 2007-11-15
CN1535150A (zh) 2004-10-06
ES2280602T3 (es) 2007-09-16
MY134059A (en) 2007-11-30
KR20040029325A (ko) 2004-04-06
SI1408964T1 (sl) 2007-06-30
PT1408964E (pt) 2007-05-31
CA2455621C (en) 2010-11-16
WO2003009835A3 (en) 2003-08-07
DK1408964T3 (da) 2007-05-21
WO2003009835A2 (en) 2003-02-06
CY1107616T1 (el) 2013-03-13
MXPA04000775A (es) 2004-04-20
US20040171645A1 (en) 2004-09-02
RU2004105844A (ru) 2005-05-10
PL208258B1 (pl) 2011-04-29
CN1292749C (zh) 2007-01-03
BR0211358A (pt) 2004-09-21
US7872030B2 (en) 2011-01-18
EP1408964B1 (en) 2007-01-24
JP2004538289A (ja) 2004-12-24
ATE352302T1 (de) 2007-02-15
HK1068793A1 (en) 2005-07-29
EP1408964A2 (en) 2004-04-21
HUP0402092A3 (en) 2010-06-28
CA2455621A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
DE602006017261D1 (de) Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
CL2007003583A1 (es) Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
CL2009000380A1 (es) Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
UY27018A1 (es) Derivados de la pirimidina
AR029412A1 (es) Forma cristalina
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
AR031679A1 (es) Una composicion farmaceutica
EA200970022A1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed